Prostate cancer screening commands strong public support, with campaigners and high-profile figures calling for a national programme — but the risks of widespread testing are sharply acknowledged by the experts charged with assessing the evidence. Professor Sir Mike Richards, chairman of the UK National Screening Committee (UKNSC), told a briefing: “We absolutely recognise the strong support for prostate cancer screening amongst a large number of people, but also the very real harm that can be caused by the disease which patients, and indeed their families, experience.”
Public Support and Campaigner Disappointment
Charities, campaigners and prominent individuals have voiced their backing for more widespread screening. Prostate Cancer UK described the UKNSC’s final decision against a population-wide programme as a cause of “deep disappointment”, arguing that a mass screening effort could save thousands of lives. Six-time Olympic gold medallist Sir Chris Hoy, former prime minister David Cameron, and actor Sir Stephen Fry have all publicly supported broader testing. The strength of feeling reflects the scale of the disease: prostate cancer is the most commonly diagnosed cancer in the UK, with more than 64,000 new cases each year, and it is the second most common cause of cancer death among men, accounting for around 12,300 deaths annually.
The Human Cost of Prostate Cancer
One in eight men in the UK will be diagnosed with prostate cancer in their lifetime. For Black men, the risk is significantly higher: one in four is expected to receive a diagnosis. The disease’s toll is not limited to mortality. While over nine in ten men diagnosed survive for ten years or more, the experience of aggressive cancer — particularly when it is fast-growing and detected late — can be devastating for patients and their families. Survivors often face long-term side effects from treatment, including incontinence and erectile dysfunction, but the harm of the disease itself is what drives the urgent calls for earlier detection. The UKNSC’s final recommendation reflects a difficult balance: while the committee acknowledges the suffering caused by prostate cancer, it also insists that a screening programme based on the current PSA blood test would likely cause more harm than good.
The Case Against Mass Screening
After completing its review, the UKNSC recommended against a universal screening programme for all men, including Black men and those with a family history of the disease but without a BRCA2 gene variant. The primary reason is the inadequacy of the PSA test, which has been shown in multiple large-scale trials to be insufficiently accurate for widespread use. The test can produce false positives, miss some cancers, and lead to overdiagnosis — picking up cancers that would never have caused symptoms or harm. The committee estimates that for every 1,000 men aged 50 to 60 who are screened, up to two lives might be saved, but as many as 20 men could be overdiagnosed, with 12 potentially undergoing unnecessary treatment that carries lifelong side effects. Professor Sir Mike Richards highlighted that many men will live full lives without prostate cancer ever causing them harm, and screening can only help if it can reliably distinguish between harmful and harmless disease — something the current technology cannot do.
Targeted Screening for BRCA2 Carriers
The UKNSC did recommend a limited targeted programme for men aged 45 to 61 who have a confirmed BRCA2 gene change that increases their cancer risk, together with a family history of breast, ovarian, pancreatic or prostate cancer. Those men will be offered a PSA test every two years. The decision is based on evidence that men with a BRCA2 variant and relevant family history are more likely to develop fast-growing, aggressive prostate cancer. For 100 men with a BRCA2 variant, between 21 and 35 are expected to develop prostate cancer before the age of 80. Notably, a draft recommendation in November 2025 had also included men with BRCA1 gene changes, but they were excluded from the final guidance because recent data suggested their risk is significantly lower.
Uncertainty for Other High-Risk Groups
The UKNSC did not recommend targeted screening for Black men or for men with a family history of cancer but without a BRCA2 mutation. For Black men, the committee said there is “ongoing uncertainty on whether screening would cause more good than harm.” Some doctors have called the decision not to screen older Black men a “scandal”, arguing that the committee has misjudged the evidence and that Black men face fundamental inequality because of their higher risk of both developing and dying from prostate cancer. Chiara De Biase, director of health services, equity and improvement at Prostate Cancer UK, expressed concern that the committee’s approach may leave the highest-risk groups behind.
Ongoing Research and Future Directions
A major £42 million trial called TRANSFORM is underway, aiming to find the best method for screening men for prostate cancer. The trial is comparing various techniques including PSA blood tests, genetic tests and fast MRI scans to establish the safest, most accurate and cost-effective approach. Initial results are expected within two years, and the UKNSC has committed to reviewing that new evidence. Researchers are also exploring genetic testing — such as polygenic risk scores derived from saliva tests — and other biomarkers as potential screening tools for identifying men at higher genetic risk. MRI scans are being evaluated for their role in early detection. Professor Sir Mike Richards acknowledged that the committee will revisit its position as new evidence emerges.
In the meantime, there is no national screening programme in the UK. Men who are concerned can ask their GP for a PSA test, and GPs are advised to counsel them on the benefits and harms. However, studies show wide variations in PSA testing rates across England, with higher rates in more affluent areas and among certain ethnic groups, raising concerns about health inequalities. Celebrity endorsements have also been linked to surges in testing. The PSA test remains controversial, described by experts such as Professor Freddie Hamdy CBE, Nuffield Professor of Surgery at the University of Oxford, and Professor Jenny Donovan OBE, Professor of Social Medicine at the University of Bristol, as a tool that can do more harm than good when used indiscriminately. Dr Ian Walker, executive director of policy at Cancer Research UK, noted that the committee’s decision reflects the current evidence, but the TRANSFORM trial may change the picture. Professor Anneke Lucassen, Professor of Genomic Medicine at the University of Oxford, emphasised that more personalised approaches — such as genetic profiling — could one day spare low-risk men from unnecessary treatment while targeting those who truly need it.